Guangdong Lung Cancer Institute was officially found in 2003. It is a research institution integrating medical practice, scientific research, and clinical teaching focusing on single disease, multidisciplinary comprehensive diagnosis and treatment, and individualized "precision diagnosis and treatment" of patients. Currently, it is composed of Division of Pulmonary Oncology, Division of Surgery, Thoracic Oncology, Radiotherapy Department, Biostatistics department, Information Center, Guangdong Provincial Key Laboratory of Translational Medicine for Lung Cancer (including the Biomaterial Library and South China Clinical Genetic Testing Center), "Evidence-Based Medicine" magazine, clinical pharmacology base and other clinical and scientific research departments. The innovative achievement of Guangdong Lung Cancer Institute has been incorporated into 27 lung cancer guidelines in 15 countries and regions around the world. The corresponding researches were published in top international academic journals including New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Nature Genetic, etc.

  The institute has been awarded National Science and Technology Progress Awards, the first prize of Chinese Medical Science and Technology Progress Awards, and the first and second prizes of Guangdong Science and Technology Progress Awards. The academic leader, Professor Yi-Long Wu, won the "Paul Bunn Oncology Science Award" of the International Society for Lung Cancer Research (IASLC), Outstanding Contribution Award for his outstanding contributions. This is the first time that the International Association for Lung Cancer Research has given this award to a Chinese clinical oncologist in the 40 years since its establishment where only 10 experts worldwide have won this honor. The distinguishing features of Guangdong Lung Cancer Institute include: 1. Precision diagnosis and treatment modality of lung cancer with multidisciplinary single disease management; 2. Standardized diagnosis and treatment model of evidence-based medicine; 3. Academic system with equal emphasis on clinical research and translational research; 4. Advanced laboratory and scientific research technology platform; 5. The development model of individualized molecular targeted therapy; 6. Comprehensive clinical services for diagnosis, treatment and prevention & prediction; 7. Minimally invasive surgery under the guidance of AI and 3D reconstruction; 8. Precision treatment strategy for lung cancer.

  Our Institute values harmonious doctor-patient relationship, striving for the utmost benefit of patients as its goal. We do extensive domestic and international exchanges, and have established cooperative relations with the United States, Britain, Italy, Denmark and other countries, established alliances with internationally renowned pharmaceutical companies, and conducted multi-level and multi-field exchange activities. Under the strategic deployment of Professor Yi-Long Wu and the leadership of the hospital, with the joint efforts of all medical staff and scientific researchers, our institute will continue to make great strides and unremitting efforts for new contributions to the prevention, diagnosis and treatment of lung cancer and translational research.